SPS 4251

Drug Profile

SPS 4251

Alternative Names: PAP-1; SPS-4251

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Airmid
  • Developer Circassia
  • Class Antipsoriatics
  • Mechanism of Action Immunosuppressants; Kv1.3 potassium channel inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Atopic dermatitis; Plaque psoriasis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Plaque-psoriasis in Germany (Topical, Ointment)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Atopic-dermatitis in United Kingdom (Topical, Ointment)
  • 16 Jul 2013 Circassia completes a phase Ib trial in Plaque psoriasis in Germany (NCT01743118)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top